EU Accelerated Assessment Tracker
Executive Summary
GSK secured accelerated assessment for dostarlimab at the European Medicines Agency but there was no such good news for Merck/AstraZeneca's selumetinib. MYR Pharmaceuticals' bulevirtide has reverted to standard review timelines.
You may also be interested in...
EMA Considers Fast-Tracking Rhythm’s Insatiable Hunger & Obesity Disorders Drug
Setmelanotide, which is being developed to treat insatiable hunger and early-onset severe obesity in people with rare genetic disorders, was also recently submitted to the US regulator for approval.
AstraZeneca/MSD’s Koselugo Among 14 New Hopefuls At EMA
New drugs from Eli Lilly, Pfizer, Janssen, GSK, Arvelle, BioCryst, Diurnal and Myovant are also among the latest products the European Medicines Agency is evaluating for potential pan-EU approval.
Ide-Cel & Enhertu Sponsors Keep Fingers Crossed For EMA Fast-Track
Companies are due to learn this week whether the European Medicines Agency will fast-track its review of their soon-to-be-filed EU marketing applications.